Bladder Cancer Research

Bladder cancer innovation spans perioperative immunotherapy, ADCs, FGFR-directed therapy, and bladder-preserving multimodality treatment.

Our Bladder Cancer Analysis

• October 2, 2026Nature MedicineuRARE-seq (non-randomized biomarker study)

  Urine Cell-Free RNA Test Detects Bladder Cancer at 95% Sensitivity and 90% Specificity, but Residual-Disease and BCG-Response Findings Rest on Small Cohorts

  uRARE-seq is a tumor-naive urine cell-free RNA (cfRNA) sequencing approach, applied to 683 urine samples from patients with cancer and controls. In the training cohort (100 controls, 151 bladder cancer samples), the detection model reached an AUC of 0.97, with a sensitivity of 95% at 90% specificity.

• September 24, 2026JAMA Oncology

  Modifiable Risk Factors Account for an Estimated 84% of the Male–Female Cancer Gap in China but 26% in the UK

  A multicohort analysis of 589,766 adults aged 40 to 74 years without prior cancer, drawn from the Shanghai Men’s Health Study, the Shanghai Women’s Health Study and UK Biobank, estimated how much of the higher cancer incidence in males is attributable to 11 lifestyle factors and health conditions.

• September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

  Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

  PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.